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Abstract Allergic rhinitis (AR), the most common allergic disorder of the airway, is often
accompanied by bronchial asthma. However, little is known about the mechanism by which AR
advances to AR comorbid with bronchial asthma (AR + Asthma). To determine the pathophys-
iologic features of AR and AR + Asthma, we examined subsets of follicular helper T (Tfh) cells
and regulatory B (Breg) cells in peripheral blood from AR and AR + Asthma patients. The results
showed polarization of Tfh2 cells within Tfh cell subsets in both AR and AR + Asthma cases.
Interestingly, the %Breg cells in total B cells were decreased in AR cases and, more extensively,
in AR + Asthma cases. Moreover, we found significant correlations of fractional exhaled nitricTfh, follicular helper T; Breg, regulatory B; Ig, immunoglobulin; Th1, type 1 helper CD4+ T; Th2, type 2
ymphopoietin; IL, interleukin; Tfh1, type 1 Tfh; Tfh2, type 2 Tfh; Tfh17, IL-17-producing Tfh; PBMC,
NO, fractional exhaled nitric oxide; SEM, standard error of the mean; SD, standard deviation; FACS,
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205Tfh2 and Breg cells in allergic rhinitis and bronchial asthmaoxide and blood eosinophil levels with the index %Tfh2 cells per %Breg cells. Our findings
indicate that relative decrease in Breg cells under the condition of Tfh2 cell skewing is a putative
exaggerating factor of AR to bronchial asthma.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Allergic rhinitis (AR) affects 10 to 20% of the population and
its increasing worldwide prevalence has made it a global
health problem [1]. AR is characterized by rhinorrhea,
sneezing and nasal congestion owing to persistent local
inflammation of nasal mucosa in the upper airway. It is well
known that AR frequently precedes bronchial asthma (in 10
to 40% of cases), and the presence of AR is considered to be a
risk factor for new onset of asthma [2]. AR concomitant with
bronchial asthma (AR + Asthma) or allergic rhinobronchitis
has a much greater effect than AR alone on quality of life
because of the severe symptoms of bronchial asthma such as
wheeze and dyspnea. Allergic airway disorders are caused by
an immunological defect based on type 1 hypersensitivity
reactions through activation of eosinophils, basophils and
mast cells and increased antigen-specific immunoglobulin E
(IgE) [3]. The clinical condition of type I hypersensitivity is
attributable to a functional imbalance of type 1 and type 2
helper CD4+ T cells (Th1 and Th2 cells, respectively) caused
by epithelial cell-derived cytokines including thymic stromal
lymphopoietin (TSLP), interleukin (IL)-25 and IL-33. Under
this condition, Th2 cells secrete IL-4, IL-5 and IL-13 to
promote unfavorable immune responses by helping B cells to
produce allergen-specific IgE in the airway [4–6]. However,
the mechanism by which AR deteriorates to AR + Asthma,
which is a more serious form of allergic airway diseases, is
still unclear.
To establish antigen-specific humoral immunity, B cells
form germinal centers of lymphoid follicles in concert with
follicular helper T (Tfh) cells, which are a class of effector
helper T cells [7]. As with conventional helper T cell subsets,
circulating Tfh cells (CD3+CD4+CXCR5+) are classified into
three distinct subsets based on expression profiles of the
chemokine receptors CCR6 and CXCR3, which are shared by
Th1 cells and Th17 cells, respectively [8,9]. Such circulating
Tfh cell subsets include type 1 Tfh (Tfh1) cells, type 2 Tfh
(Tfh2) cells, and IL-17-producing Tfh (Tfh17) cells, which can
secrete restricted repertories of the cytokines Interferon-γ,
IL-4 and IL-17, respectively, as can conventional helper T
cell subsets. Tfh2 cells, like Th2 cells, have the capacity to
help B cells produce IgE, though it is not known whether Tfh2
cells play a role similar to that of Th2 cells in the
pathogenesis of allergic disorders [8,10]. Recent investiga-
tions have revealed that the levels of IgE can be regulated by
regulatory B (Breg) cells, which produce the negative
regulatory cytokine IL-10 [11,12]. Moreover, studies using
experimental murine models have suggested that Breg cells
broadly control T cell-mediated immune responses in associ-
ation with contact hypersensitivity, bronchial asthma, exper-
imental autoimmune encephalomyelitis and collagen-induced
arthritis [13–16]. Taken together, results indicate that Tfh
cell subsets and Breg cells in peripheral blood might have anunidentified role in the regulation of clinical aspects of AR
prone to AR + Asthma.
In this study, we analyzed the expression profiles of Tfh
cell subsets and Breg cells in peripheral blood mononuclear
cells (PBMCs) from AR and AR + Asthma patients. Interest-
ingly, like the Th1/Th2 imbalance, we found a Tfh1/Tfh2
disproportion in both AR and AR + Asthma patients, showing
predominance of Tfh2 cells. Thus, polarization of type 2
cells of Th cells and that of type 2 cells of Tfh cells would
occur simultaneously in AR and AR + Asthma, by which
allergic hyperresponsiveness to external antigens is
likely to be heightened. We also obtained evidence
that the proportion of Breg cells was decreased during
disease progression from AR to AR + Asthma. Moreover, in
AR + Asthma cases, the ratio of %Tfh2 cells to %Breg cells
was significantly correlated with levels of fractional
exhaled nitric oxide (FeNO) and peripheral blood eosino-
phils, which are biomarkers of allergic airway inflammation.
Several mechanisms have been proposed to explain the
united airway theory; however, our findings suggest that
the pathogenesis underlying disease aggravation from AR to
AR + Asthma may be a functional deficit of regulatory B
cells under the condition of skewing of type 2 cell species
within helper CD4+ T cells.2. Materials and methods
2.1. Study populations
Characteristics of patients with AR (n = 23) or AR comorbid
with bronchial asthma (AR + Asthma, n = 19) and healthy
volunteers (n = 24) are summarized in Table 1. The diagnosis
of AR was established on the basis of medical history and
general nasal symptoms for at least 2 years, nasal cytology
and specific IgE to four aeroallergens (house dust mite,
Dermatophagoides pteronyssinus, Japanese white birch and
orchard grass). Subjects with bronchial asthma were diag-
nosed by questionnaires, spirometry, airway hyperreactivity
tests in response to methacholine (PC20 methacholine) and
measurement of specific IgE. FeNO levels were analyzed in
exhaled breath [17]. Levels of specific IgEs to allergens and
total IgE levels in serum were measured by ImmunoCAP
(Phadia, Uppsala, Sweden). No patient had a history of
allergen-specific immunotherapy. Treatment with antihista-
mines and corticosteroids was stopped at least 4 weeks before
the subjects entered the study. All of the healthy volunteers
had no abnormal physical and chest X-ray findings and were
negative for the CAP test. All subjects were non-smokers.
Written informed consent was obtained in all cases according
to the Declaration of Helsinki. All protocols were approved by
the Institutional Review Boards of Sapporo Medical University
Hospital and Sapporo Respiratory Hospital.
Table 1 Subject characteristics.
Healthy
(n = 24)
AR
(n = 23)
AR + Asthma
(n = 19)
Age (years) mean ± SD
(Range)
40.3 ± 12.2
(21−62)
44.1 ± 13.1
(28−69)
44.9 ± 14.4
(19−63)
Male/female (number) 9/15 9/14 10/9
Total IgE (IU/ml) mean ± SD
(Range)
32.6 ± 21.9
(2−84)
168.8 ± 254.5
(20−1243)
907.5 ± 1104.7
(43−4324)
Specific IgE
Number of positive case (%)
House dust mite 0 (0) 16 (69.6) 16 (84.2)
Dermatophagoides pteronyssinus 0 (0) 16 (69.6) 16 (84.2)
Japanese white birch 0 (0) 14 (60.9) 9 (47.4)
Orchard grass 0 (0) 8 (34.8) 8 (42.1)
Blood eosinophils (number/μl) mean ± SD
(Range)
150.1 ± 115.3
(32−400)
183.7 ± 140.0
(38−461)
539.7 ± 389.6
(106−1311)
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Panels of directly conjugated anti-human monoclonal anti-
bodies were used to measure lymphocyte species of Tfh cells
(anti-CD3-APC, anti-CD4-APC-Cy7, anti-CXCR5-PerCP-Cy5.5),
Tfh cell subsets (anti-CD3-FITC, anti-CD4-APC-Cy7, anti-
CXCR5-PerCP-Cy5.5, anti-CCR6-APC, anti-CXCR3-PE-Cy7),
and Breg cells (anti-CD19-APC-Cy7, anti-CD24-PerCP-Cy5.5,
anti-CD27-FITC) gated by cells negative to anti-CD3-APC. All
monoclonal antibodies were purchased from BD Biosciences
(San Jose, CA, USA).
2.3. Flow cytometry
Heparinized PBMCs were isolated from fresh blood speci-
mens by centrifugation over a discontinuous density gradient
(Lympholyte®-H; Cedarlane, Burlington, ON, Canada). Cell
staining and flow cytometry using FACSCanto™ II and
FACSAria™ II (BD Biosciences) were performed as previously
described [18].
2.4. Statistical analysis
All data are shown as means ± SEM. Significant differences
between specimens were determined by using Student's t
test and the Mann–Whitney U test. Correlations were
determined by Spearman's ranking. Probability values less
than 0.05 were considered significant.
3. Results
3.1. Tfh cell subsets in AR and AR + Asthma cases
As expected, serum levels of total IgE in patients with AR were
elevated in comparison to those in healthy controls (Fig. 1A).
When AR was combined with bronchial asthma (AR + Asthma),
total IgE and blood eosinophil levels were significantly
elevated compared to those in AR cases (Figs. 1A,B). This
indicates that a possible factor(s) would play a certain role in
upregulation of total IgE and eosinophils, causing unfavorable
allergic inflammation over the pulmonary parenchyma and inthe upper respiratory tract. Examinations of PBMCs revealed
that the ratio of circulating total Tfh cells (CD3+CD4+CXCR5+)
to CD4+ T cells (CD3+CD4+) in AR cases was comparable to that
in healthy controls and even to that in AR + Asthma cases
(Figs. 2A,B). In addition, there was no significant difference in
absolute number of total Tfh cells between the control and AR
cases or between the control and AR + Asthma cases (Fig. 2B).
In contrast to total Tfh cells, it was interesting that both AR and
AR + asthma cases had unique polarization of circulating Tfh
cell subsets, with Tfh2 cells being clearly overt (Figs. 3A–D).
The percentage (in total Tfh cells) and absolute number of
Tfh1 cells (CD3+CD4+CXCR5+CXCR3+CCR6−) in both AR and
AR + Asthma cases were significantly decreased to similar
levels compared to those in healthy controls (Fig. 3B).
Conversely, the percentage and number of Tfh2 cells
(CD3+CD4+CXCR5+CXCR3−CCR6−) in AR and AR + Asthma cases
were substantially increased compared to those in controls
(Fig. 3C). The percentage and number of Tfh17 cells
(CD3+CD4+CXCR5+CXCR3−CCR6+) in AR and AR + Asthma cases
were preserved at levels similar to those in controls (Fig. 3D).
Collectively, the results showed that patients with AR and
patients with AR + Asthma manifested similar profiles of Tfh1
and Tfh2 cells directing Tfh2 cell skewing, probably underlying
the allergic condition of these disorders. This type of skewing
of Tfh cell subsets was further supported by analysis of the
ratios of percentage of Tfh2 cells to that of Tfh1 cells in AR and
AR + Asthma cases (Fig. 3E), like the status of Th1 cells and Th2
cells as seen in allergic respiratory diseases.
3.2. Breg cells in AR and AR + Asthma cases
To further understand cues responsible for the pathogenesis
of AR and AR + Asthma, we next assessed circulating Breg
cells (CD3−CD19+CD24hiCD27+), as a negative regulator of
immunity [11], in AR and AR + Asthma cases (Fig. 4A). The
percentage of Breg cells in total B cells (CD3−CD19+) in AR
cases was clearly decreased compared to that in healthy
donors (Fig. 4B). Of note, the percentage of Breg cells in AR
was more significantly decreased when AR was comorbid
with bronchial asthma. Taken together, the results suggest a
certain role of Breg cells to limit allergic inflammations
probably by controlling allergen tolerance.
Figure 1 Serum levels of total IgE and blood eosinophils in patients with allergic rhinitis (AR) and patients with AR comorbid with bronchial
asthma (AR + Asthma). Serum levels of total IgE and blood eosinophils are shown in (A) and (B), respectively. Levels of blood eosinophils are
shown as percentage of white blood cells and absolute number (per μl blood). *P b 0.05, **P b 0.01, ns indicating not significant.
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and relative decrease in Breg cells based on
Tfh2 cell skewing
We hypothesized that Tfh2 cell skewing and relative decrease
in Breg cells play synergistic roles in the deterioration of AR to
AR + Asthma. To prove this hypothesis, we generated a new
index calculated from Tfh2 cells (%) and Breg cells (%), which
simply means the ratio of Tfh2 cells to Breg cells. The index
represents the degree of Tfh2 cell deviation and relative
decrease in Breg cells. Interestingly, the index was positively
related to the number of eosinophils in peripheral blood from
patients with AR + Asthma (Fig. 5A). The index was also
correlated with FeNO in AR + Asthma cases (Fig. 5B).
4. Discussion
In this study, we obtained evidence that patients suffering
from AR or AR + Asthma of immunological airway diseasesFigure 2 Ratios of circulating total Tfh cells in AR and AR + Asthm
(FACS) profiles indicating total Tfh cells (CD3+CD4+CXCR5+). Plots w
CXCR5. (B) Percentage of total Tfh cells in CD3+CD4+ cells and absolu
and right panels, respectively. ns indicating not significant.preferentially exhibit Tfh2 cell polarization of peripheral blood
lymphocytes. Given that AR and AR + Asthma cases have
normal levels of total Tfh cells and Tfh17 cells, such Tfh2 cell
skewing is probably attributable to increased levels of Tfh2
cells and decreased levels of Tfh1 cells within circulating Tfh
cell populations. To the best of our knowledge, this is the first
report of a Tfh1/Tfh2 imbalance in allergic disorders, though it
has been shown that patients with autoimmune diseases such
as systemic lupus erythematosus and juvenile dermatomyositis
have a dominancy of Tfh2 and Tfh17 cells [8,9,19]. Allergic
inflammatory diseases including AR, bronchial asthma, atopic
dermatitis and allergic enterocolitis are primarily based on a
disequilibrium of Th1 and Th2 cells, which causes Th2
cell-mediated inflammatory lesions in affected tissues. Inter-
estingly, we found that patients with AR or AR + Asthma show
CD4+ T cell polarization not only to Th2 cells but also to Tfh2
cells. Th2 cells and Tfh2 cells can produce IgE-related
cytokines such as IL-4, IL-5, and IL-13. Indeed Tfh2 cells have
the capacity to enable B cells to become IgE-producing cells
[8], and the elevated number of Tfh2 cells in AR anda cases. (A) Representative fluorescence-activated cell sorting
ere pregated on CD3+CD4+ cells and examined by the levels of
te number of total Tfh cells (per μl blood) are shown in the left
Figure 3 Polarization of circulating Tfh cell subsets in AR and AR + Asthma cases. (A) Representative FACS profiles indicating Tfh1
cells (CXCR3+CCR6−), Tfh2 cells (CXCR3−CCR6−) and Tfh17 cells (CXCR3−CCR6+). Plots were pregated on CD3+CD4+CXCR5+ cells and
examined by the levels of CXCR3 and CCR6. Numbers indicate percentage of cells in the gate. (B–D) Percentage of Tfh cell subsets in
total Tfh cells and absolute number of Tfh cell subsets (per μl blood) are shown in the left and right panels, respectively. (B) Tfh1
cells, (C) Tfh2 cells and (D) Tfh17 cells. (E) Ratio of %Tfh2 cells to %Tfh1 cells. *P b 0.05, **P b 0.01, ****P b 0.0001, ns indicating not
significant.
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antigen-specific IgE, leading to allergic inflammation. A
hallmark of Tfh cells is surface expression of CXCR5, which is
also advantageously shared by B cells [20,21]. Thus, Tfh2 cells
in AR and AR + Asthma cases are thought to easily make
contact with B cells for activation through CXCL13, a CXCR5
ligand secreted by various cells including follicular dendritic
cells, endothelial cells and also Tfh cells [22]. From this point
of view, it is possible that Tfh2 cells, like Th2 cells, contribute
to the direct pathogenesis of allergic inflammation mediated
by IgE. During the development of tissue-resident Tfh cells
from naïve helper CD4+ T cells, where a suite of genes including
Bcl6, MAF and STAT3 defines core characteristics of Tfh cells,intermediate cells of Th1/Tfh cells emerge as progenitor cells
of Tfh cells [22,23]. However, the mechanisms underlying the
development of circulating Tfh cell subsets, especially the
mechanism of Tfh2 cell skewing, remain elusive. Recent
advances in deep profiling of individual lymphocytes have
opened a new paradigm for an understanding of the immune
system [24]. Such studies may shed light on the understanding
of differentiation and/or survival of Tfh1 and Tfh2 cells and
further characterize allergy-prone macrocosm and microcosm
mediated by heterogeneous helper CD4+ T cells.
In addition to a salient feature of circulating Tfh cell
subsets, we showed for the first time a stepwise decline in
the percentage of Breg cells from a normal condition to AR
Figure 4 Percentages of circulating Breg cells in AR and AR + Asthma cases. (A) Representative FACS profiles indicating Breg cells
(CD24hiCD27+). Plots were pregated on CD3−CD19+ cells and examined by the levels of CD24 and CD27. Numbers indicate percentage
of cells in the gate. (B) Percentage of Breg cells in total CD3−CD19+ B cells and absolute number of Breg cells (per μl blood) are shown
in the left and right panels, respectively. **P b 0.01, ****P b 0.0001, ns indicating not significant.
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probably associated with serum levels of total IgE and
hyperfunction of eosinophils, in which Breg cells would play
a possible role to confine broad allergic inflammation. When
immunotherapy using an allergen is performed for reducing
symptoms of AR and bronchial asthma, the percentages of
Breg cells and regulatory T cells are increased with
alteration of serum quantities of antibody subclasses, with
the level of IgE being downregulated and levels of other
immunoglobulin subclasses including IgG4 being upregulated
[25]. Such changes in clinical markers are in part compatible
with our observations. In allergic asthma, Breg cells have an
impaired capacity to secrete IL-10 under the condition of
LPS stimulation [26]. Thus, further functional defects of Breg
cells might also occur in combined AR and asthma syndrome.
Recent investigations further suggest a possible role of IL-35
produced by Breg cells in the pathogenesis of allergic airway
diseases of rodent models [27,28]. Collectively, the results
suggest that regulatory B cells play an important part in the
transitional process from AR to AR + Asthma.
Although a functional linkage between Breg cells and
Tfh2 cells remains to be elucidated, the significant correla-
tion of the index (%Tfh2 cells divided by %Breg cells) and
inflammatory activity characteristic to type 1 hypersensitiv-
ity indicates that these cell types may contribute to theFigure 5 Correlation between eosinophil activity and the value
patients with AR + Asthma. (A) Graph showing blood eosinophils vs %
nitric oxide (FeNO) vs %Tfh2 cells per %Breg cells.spread of allergic inflammatory lesions in the nasal cavity
and through the respiratory tract as seen in AR + Asthma
cases. CD27+ Breg cells are thought to be memory B cells
because Breg cells mostly express IgG on their surface (our
observation) and have high levels of CD48 and the membrane
tyrosine phosphatase CD148, which are expressed on
activated B cells and memory B cells, respectively [11]. In
this context, functional activation of Breg cells might
simultaneously lead to modulation of components of the
memory B-cell pool through immunological intervention
using an allergen. It is generally assumed that a germinal
center reaction helped by Tfh cells results in the formation
of antigen-specific B-cell memory, though further experi-
ments are required to determine the role of Tfh2 cells during
the development of Breg cells [29]. There are also
unanswered questions regarding the possible roles of Tfh2
cells and Breg cells in allergic inflammation with group 2
innate lymphoid cells, in the generation of allergen-specific
IgE, and in the maintenance of eosinophilia [30].
In conclusion, Tfh2-dysregulated immunity underlies the
pathogenesis of respiratory allergic diseases, and a relative
decrease in Breg cells under the condition of Tfh2 cell skewing
is a putative exaggerating factor of AR to bronchial asthma.
Focusing on a modality to restore the Tfh2 cell shift and
increase Breg cells may be a viable strategy to prevent theof %Tfh2 cells divided by %Breg cells (Tfh2 (%) / Breg (%)) in
Tfh2 cells per %Breg cells. (B) Graph showing fractional exhaled
210 R. Kamekura et al.development of allergic disorders. Since bronchial asthma
based on AR is considered to be a global health problem, a
strategy to reduce the prevalence of this disease would
substantially alleviate the huge socioeconomic burden.
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